Showing results (171-180 of 255) with videos related to

Sort By:
Pageof 26
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 28, 2023
Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) studyA Bayle, L Belcaid, M Aldea, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2012
Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumorsV M Macaulay, M R Middleton, A S Protheroe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2022
Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation studyA Gazzah, P L Bedard, C Hierro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2007
Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancerL Taillade, F Penault-Llorca, T Boulet, et al.
British Journal of Cancer|March 5, 2004
ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumoursS Vicent, J M López-Picazo, G Toledo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2015
Negative prognostic value of high levels of intracellular poly(ADP-ribose) in non-small cell lung cancerJ Michels, J Adam, A Goubar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2011
Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trialsT Reiman, R Lai, A S Veillard, et al.
Lung Cancer (Amsterdam, Netherlands)|January 1, 2021
Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitorsB Abbar, V De Castelbajac, P Gougis, et al.
Respiratory Medicine and Research|September 27, 2020
Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapyC Lefebvre, E Martin, L E L Hendriks, et al.
Investigational New Drugs|April 7, 2019
Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinomaC Even, U Lassen, J Merchan, et al.
Pageof 26